Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to ...
Trulicity (dulaglutide) is not a weight loss drug, but people receiving it may lose weight. Higher doses of Trulicity typically result in more weight loss. The FDA has not approved Trulicity as a ...
Mounjaro often leads to greater reductions in hemoglobin A1C and weight compared to similar medications. Trulicity can help reduce major cardiovascular events like heart attacks in people with type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results